ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 2334

Remission Attainment in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period
Abstract Number: 2335

Defining a Basket Population for ANA+ Arthritis Trials
Abstract Number: 2336

Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis
Abstract Number: 2337

Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers
Abstract Number: 2338

Results of Single-Arm, Phase 1b Study of Anti-C1q Treatment (ANX009) Show That the Classical Pathway Is a Key Driver of Complement Activation and Consumption in Patients with Active Lupus Nephritis
Abstract Number: 2339

Fragility of Randomized Clinical Trials of Systemic Lupus Erythematosus and Lupus Nephritis Therapies
Abstract Number: 2340

Multi-targeted Therapy Better in Achieving Complete Response in Lupus Nephritis: A Systematic Review and Meta-analysis
Abstract Number: 2341

Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
Abstract Number: 2342

Modulation of B Cell and Interferon Pathways by Ianalumab in Patients with Systemic Lupus Erythematosus: Findings from a Phase 2 Clinical Trial
Abstract Number: 2343

Hydroxychloroquine Discontinuation in the Real World: Reasons, Predictive Factors and Clinical Implications
Abstract Number: 2344

Telitacicept versus Belimumab for Patients with Active Systemic Lupus Erythematosus: A Retrospective, Multicenter, Real-world Observational Study
Abstract Number: 2345

Paired Kidney Biopsies from the AURORA 2 Study of Voclosporin in Active Lupus Nephritis
Abstract Number: 2346

SLE Medication Usage and Organ Damage Among Adult SLE Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years
Abstract Number: 2347

Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus by Race and Ethnicity: A Large Post Hoc Integrated Analysis of Five Clinical Trials
Abstract Number: 2348

Incidence of Infections Among Adult Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].